✦ LIBER ✦

Long-term efficacy of biologics in dermatology

✍ Scribed by Leslie Castelo-Soccio; Abby S. Van Voorhees

Book ID: 109115972
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 106 KB
Volume: 22
Category: Article
ISSN: 1396-0296
DOI: 10.1111/j.1529-8019.2008.01213.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term safety of biologics in dermato

Long-term safety of biologics in dermatology

✍ Xinaida T. Lima; Elizabeth M. Seidler; Hermênio C. Lima; Alexandra B. Kimball 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB

Long-term efficacy of biologics in the t

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

✍ Eihab A. Alwawi; Eliana Krulig; Kenneth B. Gordon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

The long-term efficacy and safety of new

The long-term efficacy and safety of new biological therapies for psoriasis

✍ Kim A. Papp 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 258 KB

Long–Term Stabilization of Biologicals

✍ Franks, Felix 📂 Article 📅 1994 🏛 Springer Science and Business Media LLC 🌐 English ⚖ 610 KB

Long-term biological investigations in s

Long-term biological investigations in space

✍ R.G.A. Lotz; H. Fuchs; U. Bertsche 📂 Article 📅 1975 🏛 Elsevier Science 🌐 English ⚖ 741 KB

Long-term efficacy and safety of deferas

Long-term efficacy and safety of deferasirox

✍ Maria Domenica Cappellini 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial have established that, in transfusion-dependent patients with beta-thalassaemia major, deferasirox has a similar e